Variable | TotalS i †| Q1i †| Q2i †| Q3 i †| Q4i †| Q5i †| Q6i †| Q7 i †| Q8 i †|
---|---|---|---|---|---|---|---|---|---|
Randomization group: Injectable vs. Oral | 1.32 (0.81-2.16) | 1.05 (0.74-1.50) | 1.81 (1.26-2.59) | 2.40 (1.61-3.56) | 1.94 (1.26-2.98) | 1.14 (0.78-1.67) | 2.35 (1.62-3.41) | 1.16 (0.79-1.72) | 2.29 (1.51-3.48) |
Gender: Male vs. Female | 0.65 (0.41-1.03) | 0.84 (0.58-1.21) | 0.75 (0.52-1.07) | 0.82 (0.56-1.20) | 0.55 (0.36-0.86) | 0.74 (0.51-1.09) | 0.74 (0.51-1.08) | 0.86 (0.60-1.25) | 0.63 (0.42-0.96) |
Age | 0.71 (0.54-0.95) | 0.99 (0.80-1.22) | 0.81 (0.65-1.00) | 0.69 (0.55-0.86) | 0.68 (0.52-0.88) | 0.74 (0.58-0.93) | 0.79 (0.63-1.00) | 0.75 (0.60-0.94) | 0.78 (0.60-1.00) |
Ethnicity: Aboriginal vs. Non-Aboriginal | 0.70 (0.41-1.20) | 0.80 (0.53-1.22) | 0.76 (0.50-1.15) | 0.99 (0.65-1.49) | 0.55 (0.34-0.89) | 1.01 (0.67-1.54) | 0.99 (0.63-1.55) | 0.72 (0.47-1.11) | 0.50 (0.31-0.81) |
Site: Vancouver vs. Montreal | 0.97 (0.54-1.74) | 0.72 (0.45-1.16) | 1.51 (0.98-2.33) | 1.31 (0.82-2.10) | 2.16 (1.31-3.54) | 1.19 (0.75-1.88) | 1.07 (0.68-1.69) | 1.00 (0.63-1.58) | 1.74 (1.06-2.84) |
Treatment Compliance:a Yes vs. No | 1.80 (1.08-3.01) | - | 2.18 (1.51-3.12) | - | 2.44 (1.60-3.72) | 1.97 (1.37-2.86) | 2.10 (1.45-3.03) | - | 1.95 (1.29-2.94) |
Treatment Response:b Yes vs. No | - | - | 1.53 (1.09-2.13) | - | - | 1.52 (1.06-2.17) | - | - | Â |
Treatment Retention:c Yes vs. No | - | - | - | 2.31 (1.41-3.80) | - | - | - | 2.15 (1.36-3.40) | Â |
Current Psychological Symptomsd | 0.94 (0.91-0.97) | - | 0.95 (0.93-0.97) | 0.95 (0.93-0.97) | 0.95 (0.93-0.97) | 0.96 (0.94-0.98) | 0.95 (0.93-0.97) | 0.95 (0.93-0.97) | 0.95 (0.92-0.97) |
Current Physical Healthd | - | 0.95 (0.93-0.97) | - | - | - | - | - | - | - |
Current Legal Situatione | - | - | - | 0.92 (0.85-0.99) | - | - | - | - | - |
Current Drug Usee | 0.81 (0.72-0.92) | 0.96 (0.93-0.99) | - | 0.79 (0.71-0.87) | 0.89 (0.80-0.99) | 0.90 (0.82-1.00) | 0.85 (0.78-0.94) | 0.81 (0.74-0.89) | - |
Family/Social Relationse | - | - | - | - | - | - | - | - | 0.90 (0.82-0.99) |
Heroin Use at Baselinef | - | - | - | - | - | 0.96 (0.94-0.99) | - | - | - |